Invega Dose Escalation from 9 mg
If you are increasing the dose of oral Invega (paliperidone extended-release) from 9 mg daily, the next appropriate dose is 12 mg daily, which is the maximum recommended dose.
Dosing Framework
The recommended dose range for oral paliperidone ER is 3–12 mg once daily, with 6 mg/day being the standard initial target dose that requires no titration 1, 2.
For patients currently on 9 mg daily who require further dose escalation, the next step is 12 mg daily, as this represents the maximum approved dose 3, 1, 2.
Dose adjustments should be made in increments based on individual tolerability and efficacy, typically using the initial dose increment (3 mg) when escalating 1, 4.
Timing of Dose Adjustments
Allow adequate time to assess response before increasing the dose—a full therapeutic trial requires 4–8 weeks to judge efficacy 5.
After initial titration, dose increases should occur at widely spaced intervals (14–21 days minimum) to properly evaluate response and monitor for side effects 6, 5.
Peak plasma concentrations occur approximately 24 hours after dosing, and the terminal half-life is approximately 23 hours, so steady-state effects take several days to manifest 1.
Important Considerations at Higher Doses
Higher doses (9–12 mg/day) provide additional therapeutic benefit but carry dose-related increases in adverse effects, particularly extrapyramidal symptoms (EPS) 3, 2, 4.
Extrapyramidal symptoms occurred in approximately 25% of patients treated with 9–12 mg/day doses in clinical trials 2.
At the 12 mg maximum dose, carefully monitor for EPS, tachycardia, somnolence, and QTc prolongation 3, 7.
Weight gain becomes more pronounced at higher doses—clinically significant weight gain (≥5%) occurred in approximately 15% of patients during longer-term treatment 2.
Critical Pitfalls to Avoid
Do not exceed 12 mg/day—this is the maximum recommended dose for oral paliperidone ER 1, 2, 4.
Avoid using anticholinergic agents (benztropine, trihexyphenidyl) to manage EPS, as these can paradoxically worsen agitation and should not be employed 5.
Dose reductions are required in renal impairment—patients with creatinine clearance 50–80 mL/min need adjusted dosing, and paliperidone ER is not recommended when CrCl <50 mL/min 8, 1.
Monitor serum prolactin levels, as paliperidone is associated with dose-related prolactin elevation similar to risperidone 3, 2.